About HiberGene
HiberGene is a company based in Dublin (Ireland) founded in 2009 by Peter Kidney. It operates as a B2B. HiberGene has raised $14.32 million across 9 funding rounds from investors including Cantor, Enterprise Ireland and European Union. HiberGene offers products and services including LAMP Technology, HG MENINGOCOCCUS, HG GBS, and HG SWIFT. HiberGene operates in a competitive market with competitors including Inflammatix, Karius, MeMed, Visby Medical and GenMark Diagnostics, among others.
- Headquarter Dublin, Ireland
- Founders Peter Kidney
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Hibergene Diagnostics Limited
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$14.32 M (USD)
in 9 rounds
-
Latest Funding Round
Not available
-
Investors
Cantor
& 6 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of HiberGene
HiberGene offers a comprehensive portfolio of products and services, including LAMP Technology, HG MENINGOCOCCUS, HG GBS, and HG SWIFT.
Rapid amplification system for detecting infectious diseases.
Test for meningococcus meningitis detection.
Diagnostic for Group B Streptococcus.
Platform for swift molecular diagnostics.
Funding Insights of HiberGene
HiberGene has successfully raised a total of $14.32M across 9 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in HiberGene
HiberGene has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Cantor, Enterprise Ireland and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
Shackleton Ventures is focused on secondary venture and development capital investments.
|
Locked | Locked | Locked | |
|
VC firm investing in the UK and the US
|
Locked | Locked | Locked |
Investor details for HiberGene
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by HiberGene
Investment portfolio details for HiberGene
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - HiberGene
Detailed financials for HiberGene
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Hibergene Comparisons
Peer comparison for HiberGene
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of HiberGene
HiberGene operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Inflammatix, Karius, MeMed, Visby Medical and GenMark Diagnostics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of diagnostic solutions for systemic infections
|
|
| Locked | Locked | Locked |
Developer of a non-invasive pathogen blood test for the detection of infectious diseases
|
|
| Locked | Locked | Locked |
Provider of machine learning based diagnostic solutions for infectious diseases
|
|
| Locked | Locked | Locked |
Portable PCR diagnostics for infectious diseases are developed.
|
|
| Locked | Locked | Locked |
Instruments and test panels for multiplexed molecular diagnostics are provided.
|
|
| Locked | Locked | Locked |
Diagnostic technologies for infectious, cancer, and neurological diseases are developed.
|
Detailed competitors of HiberGene
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Hibergene
Complete news archive for HiberGene
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about HiberGene
HiberGene was founded in 2009 and raised its 1st funding round 6 years after it was founded.
HiberGene is headquartered in Dublin, Ireland.
HiberGene is a funded company, having raised a total of $14.32M across 9 funding rounds to date.
HiberGene Diagnostics Limited is a private Irish company that specializes in molecular technology for the in-vitro diagnostics market. It focuses on creating rapid amplification platforms to detect infectious diseases, particularly meningitis, through tests like HG MENINGOCOCCUS. Founded in 2009 by experts from the Royal Victoria Hospital in Belfast, the company collaborates with institutions such as Queens University and partners like Eiken Chemical. It operates globally, aiming to improve diagnostic precision for healthcare providers.
HiberGene's top competitors include Visby Medical, Inflammatix and MeMed.
HiberGene offers LAMP Technology, HG MENINGOCOCCUS, HG GBS, and HG SWIFT.
HiberGene has 7 investors. Key investors include Cantor, Enterprise Ireland, European Union, Medcaptain, and EIC Fund.